Skip to content
Daily Issue
Future
of Work
·
Sign in
Daily Issue → inbox:
Subscribe
F
Feed
E
Explore
B
Build
R
Roles
A
Alerts
Y
You
← Back to explore
LTZ Therapeutics
ltztherapeutics.com
Company LinkedIn →
Follow
Biotech
Redwood City, USA
Advancing myeloid cell-based immunotherapy platform
LTZ Therapeutics
Press
LTZ Therapeutics Announces FDA Clearance of IND Application for LTZ-232 to Treat Advanced Metastatic Colorectal Cancer and Other Solid Tumors
Business Wire · 7/7/2026
LTZ bags $40 million as it sends first myeloid engager into clinic
The Pharma Letter · 4/25/2025
LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases
Business Wire · 5/31/2023
Former Genentech execs launch new immunotherapy biotech LTZ Therapeutics
BioWorld News · 5/2/2022
LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301
Business Wire · 2/24/2025
Funding Timeline
5/9/2026
unknown
$38M
●
Last issue 3d ago
LTZ Therapeutics | Funded Work